Interviews families about gene therapy for sickle cell disease
Interviews patients and parents about gene therapy for sickle cell disease.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Registry title
- Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
- Status
- Recruiting
- People taking part
- 145 people, planned
- Started
- 1 Jun 2023
- Expected to end
- Dec 2027
- Type of study
- Observational, 7 groups
- Treatments tested
- Interview
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for patients aged 8 and above, parents or caregivers of children with a rare genetic disease, and health workers. They all take part in one video interview about gene therapy.
- Age
- 8 years and above (for patients).
- Sex
- All sexes can join.
- Disease stage
- A rare genetic disease that can be treated with gene therapy, or a bone marrow failure condition. This must be confirmed by the doctor.
- Earlier treatment
- Some groups must have had gene therapy, or a child who died 6 to 24 months ago after gene therapy. Other groups were offered gene therapy but did not have it, or were never offered it.
Main reasons for not taking part
- Cannot speak English fluently
- Cannot or will not give verbal consent
- No computer or mobile device that supports video calls
- Condition that the study doctor thinks makes taking part unsafe, such as cognitive impairment or a sudden acute illness
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- For Group 1 participants only (Undergone Gene Therapy):; Parent/caregiver whose child has undergone gene therapy. OR Parent/caregiver of a child who died after receiving gene therapy at least 6 months prior to enrollment, but no more than 24 months prior to enrollment, to be contacted no sooner than 3 months after the death has occurred and no longer than 2 years. OR Patients age 8 and above who have undergone gene therapy; Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection; Must be willing to provide verbal informed consent; Release of information form signed by participant providing our study team with permission to contact healthcare provider to verify their diagnosis and receipt of gene therapy (if received); Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy; A positive confirmation on receipt of gene therapy and type received from their healthcare provider (only for those received gene therapy)
- For Group 2 participants only (Offered, but did not Undergo Gene Therapy):; Parent/caregiver of children (or patients 8 and above ) with a rare genetic disease who had been offered but were not eligible for a trial or decided against receiving gene therapy; Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection; Must be willing to provide verbal informed consent; Signed release of information form providing GeneTx study team with permission to contact participant's healthcare provider to verify the diagnosis; Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy
- For Group 3 participants only (Provider Interviews):; Healthcare worker who has provided care to ≥ 2 patients receiving gene therapy; Willingness to participate in one-on-one video (or in-person) interview with a study team member using a personal mobile device or computer with working internet connection; Informed consent from a study participant
- For Group 4 participants only (Undergone Gene Therapy for Bone Marrow Failure Condition):; Parent/caregiver whose child has undergone gene therapy. OR Parent/caregiver of a child who died after receiving gene therapy at least 6 months prior to enrollment, but no more than 24 months prior to enrollment, to be contacted no sooner than 3 months after the death has occurred and no longer than 2 years. OR Patients age 8 and above who have undergone gene therapy; Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection; Must be willing to provide verbal informed consent; Release of information form signed by participant providing our study team with permission to contact healthcare provider to verify their diagnosis and receipt of gene therapy (if received); Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy; A positive confirmation on receipt of gene therapy and type received from their healthcare provider (only for those received gene therapy)
- For Group 5 participants only (Offered, but did not Undergo Gene Therapy for Bone Marrow Failure Condition ):; Parent/caregiver of children (or patients 8 and above ) with a bone marrow failure disease who had been offered but were not eligible for a trial or decided against receiving gene therapy; Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection; Must be willing to provide verbal informed consent; Signed release of information form providing GeneTx study team with permission to contact participant's healthcare provider to verify the diagnosis; Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy
- For Group 6 participants only (Never offered gene therapy for Bone Marrow Failure Condition):; Parent/caregiver of children (or patients 8 and above ) with a bone marrow failure disease who had not been offered gene therapy; Willingness to participate in one-on-one video interview with a study team member using a personal mobile device or computer with working internet connection; Must be willing to provide verbal informed consent; Signed release of information form providing GeneTx study team with permission to contact participant's healthcare provider to verify the diagnosis; Successful verification of diagnosis of rare genetic disease targeted for treatment using gene therapy
- For Group 7 participants only (Provider Interviews for Bone Marrow Failure Condition):; Healthcare worker who has provided care to ≥ 2 patients receiving gene therapy; Willingness to participate in one-on-one video (or in-person) interview with a study team member using a personal mobile device or computer with working internet connection; Informed consent from a study participant
Who cannot take part
- Condition or chronic illness, which in the opinion of the PI/Co-I, makes participation unsafe or untenable (i.e., cognitive impairment, concurrent acute morbidity)
- Participants who are unable to converse fluently in English will be excluded
- Inability or unwillingness of research participant to give verbal informed consent
- Participants who lack access to a computer or mobile device that supports video communications will be excluded
Where in United States
- St. Jude Children's Research HospitalMemphis, United StatesContact: Liza-Marie Johnson, MD, MPH, MSBTaking people
About the trial
What the trial wants to find out
This prospective mixed-method interview study aims to qualitatively describe the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases among patients and parents of children with a rare disease targeted for treatment using gene therapy techniques. Using learned insights, the team will develop an online platform providing educational content and patient decision aids for patients and their families.
The 7 groups in the trial
- Young Adult
15-25 parents/families of children (patients aged 8 and above) with rare genetic diseases, who have recently received gene therapy
Treatment: Interview
- Parent/caregiver
10-20 patients/families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or who were ultimately not eligible for a clinical trial.
Treatment: Interview
- Healthcare Worker
10-20 health care workers' who provide care to patients receiving gene therapy.
Treatment: Interview
- Bone marrow failure condition (received gene therapy)
5-10 parents/families of children with a bone marrow failure condition, who has undergone gene therapy, OR parent/caregiver of a child who died after receiving gene therapy at least 6 months prior to enrollment, but no more than 24 months prior to enrollment OR patients age 8 and above who have undergone gene therapy
Treatment: Interview
- Bone marrow failure condition (did not receive gene therapy)
5-10 parent/caregiver of children (or patients 8 and above) with bone marrow failure conditions who were offered but have decided against receiving gene therapy or who were ultimately not eligible for a clinical trial
Treatment: Interview
- Bone marrow failure condition (never offered gene therapy)
30-40 parent/caregiver of children (or patients 8 and above) with a bone marrow failure condition who were never offered gene therapy
Treatment: Interview
- Healthcare Workers (for bone marrow failure condition)
10-20 health care workers who provide care to patients receiving gene therapy for bone marrow failure conditions.
Treatment: Interview
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
- Plain-language title
- Interviews families about gene therapy for sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 August 2026